323 related articles for article (PubMed ID: 27655283)
41. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma.
Mustafa S; Pan L; Marzoq A; Fawaz M; Sander L; Rückert F; Schrenk A; Hartl C; Uhler R; Yildirim A; Strobel O; Hackert T; Giese N; Büchler MW; Hoheisel JD; Alhamdani MS
Oncotarget; 2017 Feb; 8(7):11963-11976. PubMed ID: 28060763
[TBL] [Abstract][Full Text] [Related]
43. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
44. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
45. Tailored liquid chromatography-mass spectrometry analysis improves the coverage of the intracellular metabolome of HepaRG cells.
Cuykx M; Negreira N; Beirnaert C; Van den Eede N; Rodrigues R; Vanhaecke T; Laukens K; Covaci A
J Chromatogr A; 2017 Mar; 1487():168-178. PubMed ID: 28153450
[TBL] [Abstract][Full Text] [Related]
46. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
47. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
[TBL] [Abstract][Full Text] [Related]
48. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma.
Moore HB; Culp-Hill R; Reisz JA; Lawson PJ; Sauaia A; Schulick RD; Del Chiaro M; Nydam TL; Moore EE; Hansen KC; D'Alessandro A
Am J Surg; 2019 Dec; 218(6):1206-1212. PubMed ID: 31514959
[TBL] [Abstract][Full Text] [Related]
49. Serum and tissue metallome of pancreatic ductal adenocarcinoma.
Byeon S; du Toit-Thompson T; Hipperson L; Maloney S; Wenzel R; Gill AJ; Samra JS; Mittal A; Sahni S
Cancer Sci; 2024 May; 115(5):1446-1458. PubMed ID: 38438247
[TBL] [Abstract][Full Text] [Related]
50. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
51. Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling.
Wen S; Zhan B; Feng J; Hu W; Lin X; Bai J; Huang H
BMC Cancer; 2017 Nov; 17(1):708. PubMed ID: 29096620
[TBL] [Abstract][Full Text] [Related]
52. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
53. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
[TBL] [Abstract][Full Text] [Related]
55. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer.
Martín-Blázquez A; Díaz C; González-Flores E; Franco-Rivas D; Jiménez-Luna C; Melguizo C; Prados J; Genilloud O; Vicente F; Caba O; Pérez Del Palacio J
Sci Rep; 2019 Dec; 9(1):20198. PubMed ID: 31882610
[TBL] [Abstract][Full Text] [Related]
56. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution.
Napoli C; Sperandio N; Lawlor RT; Scarpa A; Molinari H; Assfalg M
J Proteome Res; 2012 Feb; 11(2):1274-83. PubMed ID: 22066465
[TBL] [Abstract][Full Text] [Related]
57. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma.
Nissen NI; Kehlet S; Johansen AZ; Chen IM; Karsdal M; Johansen JS; Diab HMH; Jørgensen LN; Sun S; Manon-Jensen T; He Y; Langholm L; Willumsen N
Int J Cancer; 2021 Jul; 149(1):228-238. PubMed ID: 33687786
[TBL] [Abstract][Full Text] [Related]
58. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
[TBL] [Abstract][Full Text] [Related]
59. Untargeted Comprehensive Two-Dimensional Liquid Chromatography Coupled with High-Resolution Mass Spectrometry Analysis of Rice Metabolome Using Multivariate Curve Resolution.
Navarro-Reig M; Jaumot J; Baglai A; Vivó-Truyols G; Schoenmakers PJ; Tauler R
Anal Chem; 2017 Jul; 89(14):7675-7683. PubMed ID: 28643516
[TBL] [Abstract][Full Text] [Related]
60. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
